Axsome Therapeutics Balance Sheet
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics financial position
At the end of fiscal 2025, Axsome Therapeutics reported total assets of $689.8 million, up 21.3% from a year earlier against total liabilities of $601.5 million. Shareholders' equity stood at $88.3 million, or 12.8% of assets. The company held $322.9 million in cash and equivalents against $187.7 million of debt, a net cash position of $135.2 million.
The current ratio (current assets divided by current liabilities) was 1.55, meaning short-term assets cover obligations due within a year. Debt-to-equity was 2.13.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 322.93M | 315.35M | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M | 13.97M | 34.02M | 36.62M |
| Receivables | 224.46M | 142.00M | 94.82M | 37.70M | — | — | — | — | — | — |
| Inventory | 27.94M | 15.73M | 15.13M | 4.32M | — | — | — | — | — | — |
| Total Current Assets | 588.99M | 485.06M | 504.26M | 245.64M | 86.52M | 184.02M | 220.38M | 15.22M | 35.30M | 38.00M |
| Property, Plant & Equipment | 562.00K | 584.00K | 846.00K | 722.00K | 283.85K | 52.65K | 30.62K | 51.83K | 68.07K | 100.73K |
| Goodwill | 12.04M | 12.04M | 12.04M | 10.31M | — | — | — | — | — | — |
| Intangible Assets | 40.52M | 46.89M | 53.29M | 59.66M | — | — | — | — | — | — |
| Total Assets | 689.80M | 568.50M | 588.24M | 331.48M | 87.79M | 186.13M | 220.55M | 15.38M | 35.56M | 38.21M |
| Accounts Payable | 65.54M | 72.00M | 40.68M | 38.60M | 13.15M | 13.50M | 10.94M | 3.69M | 3.44M | 4.08M |
| Short-Term Debt | 70.00M | 0 | — | — | — | — | 2.60M | 3.29M | 3.27M | 269.16K |
| Total Current Liabilities | 378.84M | 230.10M | 138.85M | 96.56M | 23.07M | 23.44M | 24.49M | 10.82M | 12.18M | 7.17M |
| Long-Term Debt | 117.75M | 180.71M | 178.07M | 94.26M | 49.09M | 48.32M | 17.33M | 3.62M | 6.66M | 9.47M |
| Total Liabilities | 601.51M | 511.48M | 397.26M | 221.92M | 72.15M | 72.34M | 41.83M | 14.44M | 18.84M | 16.64M |
| Shareholders' Equity | 88.30M | 57.02M | 190.98M | 109.56M | 15.63M | 113.79M | 178.72M | 937.92K | 16.72M | 21.57M |
| Retained Earnings | -1.31B | -1.12B | -835.57M | -596.33M | -409.20M | -278.80M | -175.90M | -107.55M | -76.58M | -47.64M |
| Total Debt | 187.75M | 180.71M | 178.07M | 94.26M | 49.09M | 48.32M | 19.93M | 6.91M | 9.93M | 9.74M |
| Net Cash (Debt) | 135.19M | 134.64M | 208.12M | 106.58M | 37.38M | 135.55M | 200.03M | 7.06M | 24.09M | 26.88M |
| Shares Outstanding | 50.88M | 48.67M | 47.35M | 43.50M | 37.82M | 37.37M | 36.93M | 30.09M | 25.49M | 19.15M |
This table shows 10 annual periods of Axsome Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a balance sheet?